SCHEMBL4071497

SCHEMBL4071497

CC(/C=C\O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 5/20 0.48
ADRA2C P18825 2/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
ADRA2A P08913 1/20 0.41
HIF1A Q16665 1/20 0.41
ALDH1A1 P00352 2/20 0.40
CYP2D6 P10635 2/20 0.39
CHRM2 P08172 1/20 0.39
ADRA1A P35348 1/20 0.39
RGS12 O14924 1/20 0.39
GLA P06280 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39
NFKB1 P19838 1/20 0.39
HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071499 1.00 TRPA1 (0.48) TRPA1ADRA2CKDM4ELMNAADRA2A
SCHEMBL1593600 0.80 TRPA1 (0.52) TRPA1ADRA2CKDM4ELMNAADRA2A
SCHEMBL1593601 0.80 TRPA1 (0.52) TRPA1ADRA2CKDM4ELMNAADRA2A
SCHEMBL15914233 0.78 TRPA1 (0.45) TRPA1ADRA2CKDM4ELMNAADRA2A
SCHEMBL5855165 0.78 TRPA1 (0.45) TRPA1ADRA2CKDM4ELMNAADRA2A
SCHEMBL5855141 0.78 TRPA1 (0.45) TRPA1ADRA2CKDM4ELMNAADRA2A
SCHEMBL28313082 0.77 ADRA2C (0.39) TRPA1ADRA2CKDM4ELMNAADRA2A
SCHEMBL6014583 0.76 TRPA1 (0.44) TRPA1ADRA2CKDM4ELMNAADRA2A
SCHEMBL6014580 0.76 TRPA1 (0.44) TRPA1ADRA2CKDM4ELMNAADRA2A
SCHEMBL1454752 0.76 TRPA1 (0.44) TRPA1ADRA2CKDM4ELMNAADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515724-B1 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2009-10-21 EP disclosed
US-7348440-B2 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator MERCK & CO., INC. (US) 2008-03-25 US disclosed
US-20060105997-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2006-05-18 US disclosed
EP-1515724-A4 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2005-08-17 EP disclosed
EP-1515724-A1 MITOTIC KINESIN INHIBITORS Merck & Co., Inc. (US) 2005-03-23 EP disclosed
WO-2004087050-A2 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2004-10-14 WO disclosed
WO-2003105855-A1 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060105997-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B TRPA1 4734/4885ADRA2C 4459/4885KDM4E 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.